Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to share acquisition prices:
- Ordinary Share price: 1591.00 pence
- American Depositary Share (ADS) price: $47.41
Material Changes
The filing reports increases in the notional interests of specific Directors and PDMRs in GSK Ordinary Shares and ADSs. These changes resulted from the re-investment of dividends paid on shares held in the GlaxoSmithKline 2009 Deferred Annual Bonus Plan. No material changes to the company's operations or financial position are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of insider share transactions.
Key Facts for Investor Verification
- Transactions were executed on April 13, 2015, via dividend re-investment under the 2009 Deferred Annual Bonus Plan.
- Acquisitions included both personal contribution elements and matching GSK contributions for listed executives.
- Key executives involved include Sir Andrew Witty, Dr. P J T Vallance, and Dr. M M Slaoui, among others.
- The filing does not contain financial results; investors should refer to the company's Form 20-F or quarterly reports for performance metrics.